Investigational Eye Drops (NPDR-01)

Phase 1Small molecule

Investigational Eye Drops (NPDR-01) is one of 20 small molecule programs targeting Non-Proliferative Diabetic Retinopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Proliferative Diabetic RetinopathyActive, not recruiting

Non-Proliferative Diabetic RetinopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Non-Proliferative Diabetic Retinopathy

#DrugCompanyPhaseTrials

Lucentis

Roche

Approved

1 2

Eylea

Regeneron

Approved

1 3

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Approved

1 4

Calcium Dobesilate

GGuizhou Bailing Group Pharmaceutical Co Ltd

Approved

2 5

Octreotide Depot

Novartis

Phase 3

2 6

Decadron

QQuince Therapeutics S.p.A.

Vabysmo

Glucophage

1 9

KSI-301

KKodiak Sciences Inc

Phase 3

1 10

Avastin

BBio-Thera Solutions

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Non-Proliferative Diabetic Retinopathy

NCT07198815

Clinical

Trials by Indication[1]

Non-Proliferative Diabetic Retinopathy1 trial

A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy

Not yet recruiting·SSichuan Academy of Medical Sciences·Phase 1·NCT07198815·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Investigational Eye Drops (NPDR-01). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Investigational Eye Drops (NPDR-01) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Investigational Eye Drops (NPDR-01). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSichuan Academy of Medical Sciences

Investigational Eye Drops (NPDR-01)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Non-Proliferative Diabetic Retinopathy1 trial

References

Drug Info

Quick Facts

Related News